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Glucocorticoids (GCs) are effective drugs, but their clinical use is compromised by severe
side effects including hyperglycemia, hyperlipidemia and obesity. They bind to the Gluco-
corticoid Receptor (GR), which acts as a transcription factor. The activation of metabolic
genes by GR is thought to underlie these adverse effects. We identify the bHLH factor E47 as
a modulator of GR target genes. Using mouse genetics, we find that E47 is required for the
regulation of hepatic glucose and lipid metabolism by GR, and that loss of E47 prevents the
development of hyperglycemia and hepatic steatosis in response to GCs. Here we show that
E47 and GR co-occupy metabolic promoters and enhancers. E47 is needed for the efficient
recruitment of GR and coregulators such as Mediator to chromatin. Altogether, our results
illustrate how GR and E47 regulate hepatic metabolism, and might provide an entry point for
novel therapies with reduced side effects.
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G lucocorticoids (GCs) are both widely used anti-inflammatory drugs and very potent metabolic reg-ulators. Unfortunately, elevated GC levels are associated
with metabolic disturbances like hyperglycemia, insulin resis-
tance, dyslipidemia, hepatic steatosis and obesity. These symp-
toms are hallmarks of metabolic syndrome and compromise their
long-term therapeutic use1,2.
When GCs bind to the Glucocorticoid Receptor (GR), it
translocates from the cytoplasm to the nucleus, where it regulates
gene expression both positively and negatively. GR is a nuclear
receptor known to bind to consensus DNA sequences termed
glucocorticoid response elements (GREs), but the exact
mechanisms leading to transcriptional activation versus repres-
sion are unclear3–5. In general, the desired immunosuppressant
properties of GCs are thought to be due to the repression of
inflammatory genes, while the adverse effects are believed to be
caused by the activation of metabolic GR targets6.
The past years have unveiled an extensive repertoire of inter-
acting transcription factors and coregulators that affect gene
regulation by GR. It has been shown that GR depends on the
presence of lineage-determining pioneering factors to generate
accessibility for enhancer and promoter binding and to create
cell-type-specific hormone responses5,7. Indeed, GR cistromes are
highly cell type specific (a cistrome is defined as the sum of all
binding sites in a given cell type, essentially the entire ChIP-Seq
data set). While GR is widely expressed, comparison of various
cistromes from different cell types shows very little overlap. That
means that the anti-inflammatory versus metabolic actions of GR
might be encoded by both cell type specific accessibility to
enhancers and tissue-specific crosstalk, which is in turn created
by different pioneering or interacting factors. For example, GR
binding at macrophage cis-regulatory elements occurs together
with AP-1 and NF-κB at sites specified by Pu.1 and C/EBP, while
the liver GR cistrome features co-occuring FoxA, HNF4α, HNF6
and C/EBP motifs3,8,9.
To gain a deeper understanding of the mechanisms involved in
the transcriptional activation of metabolic programs in response
to GCs, we performed GR ChIP-Seq and motif analyses in mouse
livers. In addition to the motifs described above, we found an E-
Box specifically enriched near GREs in hepatic promoters and
enhancers. This particular E-Box was predicted to be bound by
the basic helix-loop-helix (bHLH) transcription factor E47. E47 is
mostly known for its role in B and T cell lineage commitment,
although it is expressed in many tissues10,11. It is encoded by the
E2A or Tcf3 gene, and together with E12 (which arises from the
same E2A gene by alternative splicing), E2–2 and HEB belongs to
the class of E proteins that can heterodimerize with other bHLH
factors. Furthermore, these E proteins are inhibited by binding to
ID (Inhibitor of DNA binding) proteins, and this interplay is
necessary to drive tissue and cell type specific gene expression
programs. Importantly, mutation of all four ID proteins in mice
has been linked to phenotypic alterations in glucose, lipid and
cholesterol metabolism12.
We therefore hypothesized that co-occupancy of GR and E47
might play a role for the transcription of a subset of genes and
that E47 could modulate GR-dependent gene activation in a
tissue-specific manner. Here we show that crosstalk between E47
and GR plays a role in hepatic lipid and glucose metabolism.
Indeed, loss of E47 affects GR’s ability to upregulate metabolic
target genes. Consequently, E47 mutant mice are protected from
steroid-induced hyperglycemia, dyslipidemia and hepatic stea-
tosis. Using ChIP to map GR binding in mouse livers together
with hepatocyte-specific E47 mutant mice, we demonstrate that
GR and E47 synergize to mediate the metabolic actions of GCs at
the genomic level. We find that inactivation of E47 leads to
reduced occupancy of GR, Mediator and FoxO1 at a subset of
hepatic enhancers and promoters. We confirm the relevance of
these observations for human disease in a high throughput luci-
ferase reporter screen of human cis-regulatory sequences
responding to GCs. Thus, targeting this mechanism might pro-
vide an entry point for the development of GC therapies with
reduced metabolic side effect profiles13.
Results
GR and E2A co-occupy metabolic promoters and enhancers
in vivo. To gain mechanistic insight into GC-mediated gene
regulation in metabolic tissue, we first performed ChIP-
sequencing for GR in mouse livers collected in the late after-
noon. This is the time when endogenous corticosterone levels rise
in order to upregulate gluconeogenic genes in response to
fasting14,15. As expected, we detected strong GR binding to the
enhancers and promoters of known target genes such as Pck1,
G6pc, Per1, TAT etc. (Fig. 1, Supplementary Fig. 1 & Supple-
mentary Data 1). Bioinformatic motif analyses on GR-bound
sequences similarly revealed consensus sites for transcription
factors previously shown to co-occupy hepatic cis-regulatory
elements, namely C/EBP, HNF4α, HNF6, FoxA, Stat5 and other
nuclear receptors together with GREs3,8. Interestingly, we also
found the E47 E-Box consensus motif CANNTG enriched near
GREs (Fig. 1a). Of note, a previous study had also found an E47
motif associated with GR-bound fragments in mouse liver
samples16.
To validate that E47 plays a role for hepatic gene regulation, we
first characterized its expression profile in mouse liver: Indeed, we
detected robust levels of Tcf3 mRNA in livers collected every 4 h
throughout the day/night cycle. We also found detectable levels of
Heb, low levels of E2–2, high levels of Id2, robust levels of Id3 and
Id1 and low expression of Id4 (Supplementary Fig. 1A).
Measurable expression of the entire family of E and ID proteins
suggests a functional role in hepatocytes, although none of them
were differentially regulated in response to feeding/fasting, daily
fluctuations in endogenous corticosterone secretion or GC
treatment.
To test our hypothesis that E47 would bind together with GR
to hepatic enhancers and promoters, we next performed ChIP-
Seq using an E2A antibody in the same livers. As shown in
Fig. 1b, we actually found that the E2A and the GR cistromes
partially overlapped and that they shared a large number of
binding sites. Significantly enriched motifs within E2A ChIP
peaks included again C/EBP, HNF4α, FoxA, HNF6, E-Boxes and
GREs, together with nuclear receptor DR1 and AP-1 motifs,
underscoring the notion that E47 and GR share a set of common
target genes (Fig. 1c). Interestingly, these common targets could
be classified as genes involved in glucose and lipid metabolism.
Functional annotation of GR and E2A co-bound cis-regulatory
elements linked them to nearby genes important for glucose, lipid
and fatty acid metabolism, such as those associated with
metabolic syndrome, diabetes or hepatosteatosis (Fig. 1d). For
example, GR and E2A were both bound to the promoters or
enhancers of metabolic genes like glycerol-3-phosphate acyltrans-
ferase (Gpam), glucokinase (Gck), 24-dehydrocholesterol reductase
(Dhcr24), 3-hydroxy-3-methylglutaryl-CoA synthase 1 (Hmgcs1),
phosphoenolpyruvate carboxykinase 1 (Pck1), glucose-6-
phosphatase (G6pc) and insulin like growth factor binding protein
1 (Igfbp1) (Fig. 1e and Supplementary Fig 1B). On the other hand,
pathways that were specifically regulated by GR without E2A
were for example small molecule metabolic processes, while genes
involved in MAPK signaling showed only binding of E2A but not
GR (Supplementary Fig. 1C, D).
Taken together, our ChIP-Seq experiments reveal that E2A co-
occupies a subset of GR-bound enhancers and promoters in
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mouse liver, at target genes governing hepatic glucose and lipid
metabolism.
E47 −/− mice are protected from side effects of GC treatment.
Since our ChIP-Seq experiments pointed towards a potential co-
regulation of metabolic target genes by GR and E47, we studied
the role of E47 for GR mediated transcription in vivo. Homo-
zygous E47 mutant mice lack mature B cells due to a failure to
progress past the pro-B cell stage and have a partial early block in
T-lymphocyte development17. Still, these mice are viable and have
not yet been phenotypically characterized for metabolic functions.
We therefore treated global E47 knockout mice with exogenous
GR ligands (Supplementary Fig. 2A). If E47 is important for the
regulation of GR target genes, one would expect a reduced
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transcriptional and phenotypic response to GCs upon loss of E47
function.
Similar to human patients developing so-called steroid
diabetes, wild-type mice displayed mild hyperglycemia after
3 weeks of receiving Dexamethasone (Dex) in the drinking
water18. When subjected to i.p. glucose tolerance testing, E47
−/− mice showed protection from this effect, with blood glucose
levels being noticeably lower during the 90 min after the injection
of the glucose bolus (Fig. 2a). Pyruvate tolerance tests performed
in E47 knockouts also displayed lower values, suggesting reduced
hepatic gluconeogenesis in these mice in response to Dex
(Fig. 2b). In contrast, no difference in basal glucose or pyruvate
tolerance was observed in untreated E47−/− animals (Supple-
mentary Fig. 2B and C).
In line with these results, prominent downregulation of GR
target genes involved in gluconeogenesis (Pck1, Gck, Igfbp1…)
was observed in the livers of Dex-treated E47 knockout mice,
which was consistent with GR’s established function in the
maintenance of blood glucose15 (Fig. 2c).
We next used another protocol of chronic GC administration
to model their effect on lipid metabolism:19,20 After 3 weeks of
corticosterone (Cort) treatment, wild-type littermates developed
hepatic steatosis, while liver histology for E47−/− did not show
any pronounced accumulation of lipid droplets (Fig. 2d). In
addition, both liver and circulating triglycerides tended to be
lower in E47 mutants in response to Cort treatment, but not in
untreated mice (Fig. 2e and Supplementary Fig. 2D).
Accordingly, RNA-Seq performed on E47 mutant and wild-
type livers after either Cort or Dex treatment showed a global
deregulation of gene expression programs involved in lipid,
triglyceride and cholesterol metabolism and transport. The
reduced expression of these metabolic genes (such as apolipo-
proteins, CYP enzymes, cholesterol synthetases, Acetyl-CoA
utilizing enzymes etc.) was confirmed by qRT-PCR (Fig. 2f, g, h
and i and Supplementary Data 2). Importantly, the majority of
genes affected by the loss of E47 were downregulated, as one
would anticipate from diminished GR activity. Both GR and E47
can also act as transcriptional repressors, which might explain the
upregulated transcripts. Furthermore, we measured very few gene
expression changes in the livers of untreated E47−/− animals
(Supplementary Fig. 2E), showing that this phenotype is specific
to the GC response.
It should be noted that E47−/− mice had the same body
weight and fat mass as controls (Supplementary Fig. 2F+G), but
slightly elevated basal corticosterone levels, as could be explained
by feedback on the hypothalamic-pituitary-adrenal (HPA) axis.
When subjected to a Dex suppression test, both E47 −/− and
controls suppressed endogenous corticosterone production,
showing that their HPA axes were intact (Supplementary Fig. 2H).
Despite published reports on the potential role for E47 in the
regulation of adiponectin expression21,22, we did not see
differences in Adipoq mRNA levels in white adipose tissue from
Dex-treated mutants (Supplementary Fig. 2I). Moreover, RNA-
Seq expression profiles from E47−/− and WT quadriceps muscle
and visceral adipose depots did not reveal striking differences in
metabolic gene expression which would explain the observed
differences in glucose tolerance and liver fat deposition
(Supplementary Fig. 2J and K).
Interestingly, anti-inflammatory GC actions were retained in
the absence of E47: Mutant bone marrow derived macrophages
responded to Dex treatment with induction of the GR targets
Per1 and Gilz, and repression of the inflammatory targets Ccl2
and Il6 just like controls (Supplementary Fig. 2L). This was not
surprising, since E47 is not significantly expressed in macro-
phages, and we did not detect any E47 motifs enriched near GREs
in the macrophage GR cistrome9.
In summary, our data suggest that E47 knockout mice are
protected from GC-induced hyperglycemia, dyslipidemia and
hepatic steatosis due to a specific effect on metabolic gene
expression programs in the liver.
E47 modulates the GC response specifically in hepatocytes. To
confirm that the improved metabolic phenotype in response to
GC treatment was indeed caused by impaired E47 function in
hepatocytes, we generated liver-specific E47 mutants by crossing
E47 floxed alleles with the Albumin-Cre line (Supplementary
Fig. 3A)23. As shown in Fig. 3, glucose tolerance was significantly
lower in Alb-Cre x E47flox/flox (E47ΔLKO) mutants in response to
Dex treatment (Fig. 3a, Supplementary Fig. 3B), and liver his-
tology as well as liver and plasma triglyceride measurements
showed protection from hepatic steatosis and dyslipidemia in
Cort treated mice (Fig. 3b and c). Again, untreated liver-specific
E47 mutants did not display any significant differences to wild
type with respect to basal glucose tolerance, body weight or fat
mass gained on Cort (Supplementary Fig. 3C, D and E).
Concordantly, these phenotypes were again coincident with the
differential expression of metabolic gene programs governing
glucose, lipid, fatty acid and cholesterol utilization (like Pck1,
Acacb, Dhcr7 etc.) as measured by RNA-Seq (Fig. 3d and
Supplementary Data 2) and qRT-PCR in livers of Dex or Cort
treated mice (Fig. 3e and f). Of note, the RNA-Seq experiment
shows acute responses after only 1 h of Dex injection to avoid
indirect effects due to disease progression or pathological
changes.
Importantly, a substantial fraction (63–80%) of the transcripts
differentially expressed in E47 mutant mice treated with GCs
(Figs. 2 and 3) could be classified as direct GR target genes, as
defined by a nearby GR ChIP-Seq peak (Fig. 3g and Supplemen-
tary Fig. 3F). This underscores our interpretation that the loss of
E47 affects the transcriptional regulation of GR-bound loci.
In conclusion, our data demonstrate that E47 is required
specifically in hepatocytes for the activation of gluconeogenesis,
lipid and cholesterol storage and triglyceride synthesis, and that
targeting liver E47 improves metabolic parameters in response to
GCs.
Efficient regulation of metabolic genes by GR requires E47.
Since genetic loss of E47 revealed its role in the activation of
hepatic glucose and lipid metabolism by GR, we tested whether
impaired function of the receptor itself would explain its reduced
capacity. However, both total GR mRNA and protein levels were
unaffected by the loss of E47, and GR nuclear localization was
unchanged in mutant mouse livers (Supplementary Fig. 4A, B
and C).
We therefore performed Co-IP and ChIP-MS experiments to
study protein protein interactions between GR and E47 inside
their shared transcriptional complex. The E47 protein sequence
contains two predicted LXXLL nuclear receptor interaction
motifs. Indeed, we detected a weak physical interaction between
GR and E2A by Western Blot from endogenous liver IPs
(Supplementary Fig. 4D). Furthermore, we purified hepatic co-
regulators from chromatin cross-linked to GR by proteomics in
both wild type and E47 mutant livers treated with Dex (Fig. 4a
+b). We found that C/EBPs, SRCs, HNF4α, RXR, FoxO1,
Mediator subunits, chromatin remodelers and histone modifiers
were enriched together with GR. In E47 mutant livers, however,
Med16, Med23 and FoxO1 peptides were not present in the
ChIP-MS data set. (The only other proteins that were significantly
enriched in WT samples but not in E47ΔLKO were Elongation
factor Tu Tufm, Epithelial splicing regulatory protein 2 Esrp2,
YTH domain-containing protein 1 Ythdc1, Heterogeneous
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Fig. 2 E47 knockout mice are protected from GC-induced side effects. a i.p. glucose tolerance test (GTT) and b i.p. pyruvate tolerance test (PTT) of E47−/−
and WT mice on Dex. Data were analyzed by ANOVA and Bonferroni’s multiple comparison test and are shown as mean ± SEM. Asterisks indicate
significance, *P < 0.05, n= 10 per genotype (GTT); n= 7 (WT) & 9 (E47−/−) (PTT). c qRT-PCR of gluconeogenic genes in Dex-treated livers, normalized to
U36b4; data are mean ± SEM *P < 0.05, Student’s t test. n= 6 (WT) & 5–6 (E47−/−). d Liver sections stained with Oil Red O and hematoxylin and eosin
(H&E) after Cort or vehicle treatment. ×20 magnification; black scale bar: 100 μm, representative image from n= 3. e Liver and plasma triglycerides on Cort.
Data are mean ± SEM, n= 6 (WT) and 4–6 (E47−/−). f Volcano plot and GO analysis of deregulated genes (blue= downregulated; red= upregulated, FC
1.3, P < 0.05) in livers of E47−/− mice on Dex, n= 2 (WT) & 3 (E47−/−). For GO analysis a base mean cutoff > 200 was used. g qRT-PCR of metabolic
genes on Dex, normalized to U36B4. Data are mean ± SEM, *P < 0.05, Student’s t test, n= 5–7 (WT) & 4–7 (E47−/−). h Volcano plot and GO analysis of
deregulated genes (blue= downregulated; red= upregulated, FC 1.3, P < 0.05) in livers of E47−/− mice on Cort, n= 4 per genotype. For GO analysis a base
mean cutoff > 200 was used. i qRT-PCR of differentially expressed genes on Cort, normalized to U36b4; data are mean ± SEM *P < 0.05, Student’s t test. n= 4
per genotype
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nuclear ribonucleoprotein L Hnrnpl and the Ribosomal protein
L15 Mrpl15).
Med23, Med24 and Med16 are components of the Mediator
complex which acts as a bridge between specific transcription
factors and the general RNA Polymerase II transcription
machinery24. Its core component Med1 was previously shown
to be required for target gene regulation by GR25. FoxO1 is a
direct transcriptional regulator of hepatic lipid metabolism and
gluconeogenesis downstream of insulin signaling26. Thus, we
hypothesized that close binding of GR and E47 at certain loci is
required to assemble a critical mass of transcriptional regulators
for efficient activation of these genes. We would like to point out
that we did not measure reduced mRNA expression of either
Mediator components or FoxO1 itself in E47 mutant tissue
(Supplementary Fig. 4A).
For that reason, we performed ChIP-qPCR studies for GR,
Med1 and FoxO1 on hepatic cis-regulatory elements in both WT
and E47 mutant livers. As shown in Fig. 4c, we found that loss of
E47 led to reduced recruitment of GR itself at certain metabolic
loci (such as Apoa4, Dhcr24, Gpam, Hmgcr or Pck1), consistent
with E47’s known function as a lineage determining pioneer
factor providing chromatin accessibility27. We also found
diminished occupancy of Med1 and potentially FoxO1 at some
of these sites, for example, the Gpam enhancer, the Apoa4
promoter and the Pck1 promoter (but not at the Acacb locus).
These data suggest that E47 is necessary for binding of GR,
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upregulated, FC 1.3, P < 0.05) in E47ΔLKO livers after 1 h Dex (n= 3). For GO analysis a base mean cutoff > 200 was used. e qRT-PCR of gluconeogenic
genes in livers on Dex, normalized to U36b4. The data are mean ± SEM, *P < 0.05, Student’s t test, n= 6. f qRT-PCR of metabolic genes after Cort,
normalized to U36b4. The data are mean ± SEM, *P < 0.05, Student’s t test, n= 5. g Percentage of genes differentially expressed in E47mutant mice (Fig. 2
and 3) which harbor a detectable GR ChIP peak nearby
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Mediator and possibly FoxO1 to the promoters and enhancers of
certain common target genes, and for their efficient induction by
GCs (Supplementary Fig. 4E).
Taken together, we find that co-occupancy of GR and E47 on a
subset of liver enhancers is required for effective loading of the
Mediator complex and transcriptional activation of metabolic
gene expression by GR and FoxO1 in response to GCs.
E47 affects the physiological response to fasting. Endogenously,
an important function of GCs is the maintenance of blood
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glucose during times of fasting, when hormone levels are elevated.
To test whether our observed coregulation of metabolic programs
by GR and E47 also contributes to the physiological response to
fasting, we withdrew food from both total and liver-specific E47
mutants and controls for up to 48 h. Under these conditions,
liver-specific Alfp-Cre GRflox/flox mice were reported to become
hypoglycemic15. As shown in Fig. 5a, elevation of GC levels upon
fasting similarly led to reduced occupancy of GR and Med1 at the
Apoa4, Dhcr24, Gck, Gpam, Pck1 etc. cis-regulatory elements in
the absence of E47 (see also Supplementary Fig. 5A, B, C). This
was accompanied by a slight reduction in the expression levels of
common metabolic target genes such as Acacb, Apoa4 and Pck1
(Fig. 5b). Despite this reduced GR activity at the genomic level,
neither global nor liver-specific E47 mutants displayed fasting
hypoglycemia (Fig. 5c and Supplementary Fig. 5D). The mice
show a tendency towards lower serum glucose levels after 24 h of
fasting, but their reduction in hepatic gluconeogenesis is most
likely compensated by the kidney, as has been shown for GR
itself28. However, loss of E47 resulted in lower hepatic triglyceride
contents in fasted mice (Fig. 5d and Supplementary Fig. 5E),
which together with reduced metabolic gene expression points to
a role for E47 in the physiological adaptation to starvation.
In conclusion, E47 appears to be involved in adequate gene
activation of GR target genes during the hepatic response to
fasting, which mainly affects triglyceride storage and utilization
rather than circulating glucose.
Human GR targets are co-regulated by E47. To test whether this
E47 mediated metabolic response to GCs is conserved between
mice and humans, we screened a set of 162 human cis-regulatory
sequences predicted to be regulated by GR in a high throughput
luciferase reporter assay. In this assay, cells were transiently
transfected with commercially available GR-responsive reporter
constructs in medium supplemented with either Cortisol or
Dexamethasone (or vehicle). Luciferase activity was measured
and normalized, and individual reporter sequences were classified
into those mediating either activation or repression (or not
responding) by GCs (Fig. 6a; Supplementary Data 3). For
example, around 40 human reporters were downregulated, while
more than 80 were induced, at least twofold by GCs. As expected,
classical GRE consensus sequences were found enriched in both
positive and negative human cis-regulatory elements. Interest-
ingly, around half (47%) of all activated reporter sequences fea-
tured an identifiable E47 motif, which means E47 consensus sites
were significantly enriched near GREs in human promoters or
enhancers activated by GR (Fig. 6b).
Co-transfecting these reporters with expression vectors for
either human GR or E47 alone, or GR together with E47, indeed
showed induction of luciferase activity only when both transcrip-
tion factors were present (Fig. 6c). Mutation of the predicted E-
Box motifs, for example in the ATP2B3 promoter, prevented
regulation by E47 and abrogated this positive effect (Fig. 6d).
Furthermore, co-transfection with an expression construct for the
human inhibitor ID3 also abolished this cooperative induction, as
shown here for the DPEP1 promoter (Fig. 6e). These results show
that E47 binds to and activates E-Boxes in human promoters or
enhancers together with GR.
Taken together, our luciferase reporter data set demonstrates a
conserved function for E47 in the transcriptional activation of
certain human gene programs by GCs.
Discussion
GCs are a linchpin of anti-inflammatory therapy, but their utility
is eventually limited by considerable side effects, including
hyperglycemia, obesity, dyslipidemia or hypertension29.
Separating the beneficial immune suppressive actions from their
adverse metabolic effects is the ultimate goal for the development
of safer drugs30. In general, downregulation of GR target genes is
assumed to be crucial for the anti-inflammatory actions, while
upregulation is thought to underpin the undesirable effects.
Unfortunately, compounds such as SEGRAMs (selective GR
agonists and modulators), which favor the repressive GR func-
tions over the activating potential, have not been very
successful6.
We have identified E47 as a transcription factor cooperating
with GR specifically in the transcriptional activation of metabolic
gene networks in the liver. Consequently, E47 mutant mice are
protected from GC-induced hyperglycemia, hyperlipidemia and
hepatic steatosis. We could show that the presence of E47 is
required for efficient GR binding at a subset of liver-specific
metabolic promoters and enhancers. Interestingly, loss of E47
also affects the recruitment of the Mediator complex and FoxO1
(Fig. 7).
These observations agree with E2A’s known role as lineage
determining pioneering factor. For example, E47 has been shown
to affect Pu.1 occupancy during B cell maturation27. Previous
genomic studies in lymphoid cells have also hinted at a possibility
of E47 regulating genes involved in lipid metabolism31. In addi-
tion, E47 has been linked to FoxO1 in a common pathway, albeit
in B cells, with E47 being upstream of FoxO132,33. We have now
uncovered a novel role for E47 in modulating nuclear receptor
and potentially FoxO1 function in the liver. All FoxO1/3/4 factors
play vital roles in mammalian glucose homeostasis. FoxO1 is a
prominent regulator of hepatic gluconeogenesis in response to
insulin signaling34. Similar to our findings, liver-specific FoxO1/3/
4 mutant mice also display lower blood glucose levels and
improved glucose and pyruvate tolerance35. Moreover, FoxO1
was recently shown to synergize with GR in hepatic glucose
production and lipogenesis, for example in response to both
insulin and Dex on the Gck promoter36. The FOX consensus
motifs that we identified in the GR and E2A cistromes are mainly
co-occupied by GR and the FoxA factors8, but could of course be
recognized equally well by FoxO1.
Mediator is a large complex that is generally required for
transcription by RNA Polymerase II. It serves as a central scaffold
that relays signals from transcription factors bound to enhancers
(such as GR) to the transcription initiation machinery assembled
at promoters37. Importantly, liver-specific Med1 mutant mice are
also protected from GC-induced hepatic steatosis due to down-
regulation of GR target genes responsible for glucose and lipid
metabolism38. Further agreeing with our findings, liver-specific
deletion ofMed23 has been reported to improve lipid profiles and
glucose tolerance by affecting the transcriptional activity of
FoxO139. Reduced binding and transcriptional activity of GR,
FoxO1 and Mediator in the absence of E47 therefore presents a
likely molecular mechanism underlying our phenotype.
One promising case of a tissue-selective modulator of GC
signaling appears to be treatment with an LXRβ antagonist:
Interestingly, mice treated with GSK2033, as well as LXRβ
knockout mice, are also spared from the diabetogenic effects of
exogenous GC administration. Mirroring our results, Patel et al.
report reduced recruitment of Med1 and GR itself to the Pck1
promoter in these mice40,41. We did not see lower expression of
either LXRα or LXRβ mRNA in E47 mutant livers (Supplemen-
tary Fig. 4A), but we identified nuclear receptor DR1 motifs in
both the GR and E2A cistromes. Since the LXR heterodimer
partner RXR was co-purified with GR in our proteomics
experiment, it is conceivable that GR, E47 and LXRβ share a
common set of overlapping metabolic target genes, such as Pck1.
Loss of either LXRβ or E47 might therefore exert its beneficial
effects via a similar mechanism.
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Taken together, we have identified a novel role for E47 in
metabolic gene regulation in hepatocytes in response to GCs. We
have not only shown that targeting E47 might be a novel
approach to eliminate certain side effects of GC treatment, while
maintaining their potent anti-inflammatory properties, but pre-
sent a case of cell-type and locus-specific gene regulation by GR.
E47 only shares a subset of target genes with GR and therefore
modulates the GC response in a specific manner. Since
this function is conserved on several human promoters and
enhancers, one might speculate that the presence, absence or
the difference in E47 expression levels might influence patients’
sensitivity to GCs in several different scenarios. Finally,
this shared GR- and E47-bound, deregulated target gene set
which is responsible for the protective effect, might present a
further entry point for the development of alternative therapeutic
strategies.
Methods
Animals. E47 knockout and E47 floxed alleles were bred on a C57BL/6 back-
ground17. For E47 knockout mice, wild-type littermates served as controls. E47
floxed mice were crossed with hepatocyte-specific Albumin (Alb)-Cre mice
obtained from JAX (B6.Cg-Tg(Alb-cre)21Mgn/J). Alb-Cre negative floxed litter-
mates served as controls. Mice were housed in a controlled SPF facility with a 12 h
dark/light cycle at an ambient temperature of 23 °C with constant humidity and fed
ad libitum with regulator chow diet (Altromin GmbH). For all experiments, 10- to
16-week-old males were used. Formal ethical approval for animal experiments was
obtained from the relevant authorities (LAGeSo Berlin, Reg 0103/11; district
government of Upper Bavaria 2532–158–2014) in accordance with MDC &
HMGU guidelines for the care and use of animals.
Chromatin Immunoprecipitation (ChIP). ChIP was performed as previously
described:9 Mouse livers were harvested, snap-frozen and homogenized in lysis
buffer (10 mM Hepes-KOH, 10 mM KCl, 5 mM MgCl2, 0.5 mM DTT) using the
TissueLyser (Qiagen) with steel beads. Lysates were passed through a cell strainer
and cross-linked in 1% formaldehyde for 15 min and quenched with 0.2 M glycine
for 5 min. Chromatin was sonicated to a 0.1–1 kb size using a Bioruptor (Diag-
enode) and incubation with the following antibodies was set up overnight: rabbit
αGR (#24050–1-AP, Proteintech), rabbit αE2A (SC-349 × , Santa Cruz Bio-
technology), rabbit IgG (#2729, Cell Signaling), rabbit αMed1 (#A300–793A,
Bethyl laboratories) and rabbit αFoxo1a (#ab39670, Abcam). For ChIP-Sequencing,
8 μg of each antibody was used. For ChIP qPCR, 3 μg of each antibody was used.
The chromatin complexes were immunoprecipiated using Dynabeads M-280
(Invitrogen). ChIP DNA was purified and quantified using the Power SYBR Green
Master Mix (Life Technologies) in a ViiA 7 Real-Time PCR System (Thermo
Fischer Scientific). Primers for ChIP qPCR are listed in Supplementary Table 1a.
ChIP-sequencing and data analysis. Libraries were prepared using the KAPA
Hyperprep Kit (Kapa Biosystems, KK8504). Illumina compatible adapters were
synthesized by IDT (Integrated DNA Technologies) and used at a final concentra-
tion of 68 nM. Size-selection (360–610 bp) of adapter-ligated libraries was performed
using 2% dye free gels (#CDF2010, Sage Science) in a Pippin Gel station (Sage
Science). qPCR was used to estimate library concentrations with the KAPA Library
Quantification Kit (#KK4873, Kapa Biosystems). Library quality was verified using
the Agilent High Sensitivity DNA Kit (Agilent) in a 2100 Bioanalyzer (Agilent).
Libraries were subjected to NGS on an Illumina HiSeq4000. Reads were aligned to
the mouse mm10 reference genome using BWA-MEM version 0.7.1342 and
duplicates were removed using Picard Tools version 2.8.3 (http://picard.sourceforge.
net/). Reads were filtered for uniquely mapped read pairs with samtools43 and
downsampled to 18 mio (GR ChIP-Seq) or 22 mio (E2A ChIP-Seq) read pairs (see
https://github.com/FranziG/E47KO-liver). To visualize the tracks, mapped reads were
converted to bedGraph using HOMER version 4.927, filtered for called peak regions ±
2 kb and displayed on the UCSC genome browser. Peaks were called using MACS2
version 2.1.1.2016030944 and Gene Ontology analysis performed with GREAT45.
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Fig. 5 E47 is partially involved in the hepatic response to fasting. a ChIP-qPCR in fasted E47ΔLKO and control livers shows binding of GR and Med1 at
metabolic promoters/enhancers. The data are fold enrichment over IgG, n= 6 (Ctrl) and 4 (E47ΔLKO). The data are mean ± SEM, *P < 0.05, **P < 0.01,
Student’s t test. b qRT-PCR of metabolic genes in fasted livers, normalized to U36b4. (Gpam transcripts were very low or undetectable in this experiment.)
Data are mean ± SEM, n= 5–7 (WT) & 4–5 (E47−/−). c Blood glucose levels of E47−/− mice and controls measured at 0 h, 24 h and 48 h of fasting. The
data are mean ± SEM, n= 6–8 (WT) & 4–5 (E47−/−). d Liver triglycerides in 48h-fasted E47−/− mice and controls. The data are mean ± SEM, n= 7
(WT) & 4 (E47−/−)
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Motif enrichment and read distribution analyses around GR peaks were conducted
with HOMER. All scripts are deposited at github (https://github.com/FranziG/
E47KO-liver). NGS data and annotated peak files can be accessed via the NCBI’s
Gene Expression Omnibus using the accession number GSE111526.
ChIP coupled to mass spectrometry (ChIP-MS). ChIP-MS was performed in
livers of Dex-injected Alb-Cre x E47flox/flox and control littermates. ChIP was
carried out as described with minor modifications. Chromatin was sonicated to an
average size of 200 bp. For each biological condition, three replicates were used.
After overnight immunoprecipitation with rabbit αGR (#24050–1-AP, Proteintech,
5 μg) and rabbit IgG (#2729, Cell Signaling, 5 μg), antibody-bait complexes were
bound by protein G-coupled Dynabeads (Life Technologies) and washed three
times with wash buffer A (50 mM HEPES pH 7.5, 140 mM NaCl, 1% Triton), once
with wash buffer B (50 mM HEPES pH 7.5, 500 mM NaCl, 1% Triton) and twice
with TBS. Precipitated proteins were eluted with an on-bead digest46. Beads were
incubated for 30 min with elution buffer 1 (2M Urea, 50 mM Tris-HCl (pH 7.5), 2
mM DTT, 20 µg/ml trypsin) followed by a second elution with elution buffer 2 (2
M Urea, 50 mM Tris-HCl (pH 7.5), 10 mM Chloroacetamide) for 5 min. Both
eluates were combined and further incubated over night at room temperature.
Tryptic peptide mixtures were acidified with 1% TFA and desalted with Stage Tips
containing 3 lavers of C18 reverse phase material and analyzed by mass
spectrometry.
Peptides were separated on 50‐cm columns packed in-house with ReproSil‐Pur
C18‐AQ 1.9μm resin (Dr. Maisch GmbH). Liquid chromatography was performed
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on an EASY‐nLC 1000 ultra‐high‐pressure system coupled through a
nanoelectrospray source to a Q-Exactive HF mass spectrometer (Thermo Fisher
Scientific). Peptides were loaded in buffer A (0.1% formic acid) and separated
applying a non-linear gradient of 5–60% buffer B (0.1% formic acid, 80%
acetonitrile) at a flow rate of 250 nl/min over 105 min. Data acquisition switched
between a full scan and 15data‐dependent MS/MS scans. Multiple sequencing of
peptides was minimized by excluding the selected peptide candidates for 25 s. All
other settings were set as previously described47.
Raw mass spectrometry data were analyzed with MaxQuant version 1.5.3.54
and Perseus version 1.5.4.1 software packages. Peak lists were searched against the
mouse UniprotFASTA database (2015_08 release) combined with 262 common
contaminants by the integrated Andromeda search engine. False discovery rate was
set to 1% for both peptides (minimum length of 7 amino acids) and proteins.
‘Match between runs’ (MBR) with a maximum time difference of 0.7 min was
enabled. Relative protein amounts were determined by the MaxLFQ algorithm with
a minimum ratio count of two48. Missing values were imputed from a normal
distribution applying a width of 0.2 and a downshift of 1.8 standard deviations.
Significant outliers were defined by permutation-controlled Student’s t test
(FDR < 0.05, s0= 1) comparing triplicate ChIP-MS samples for each antibody and
biological condition.
Co-IP and western blot. Liver nuclear extracts were immunoprecipitated in IP
buffer (20 mM Tris pH 8, 100 mM KCl, 5 mM MgCl2, 0.2 mM EDTA, 20% gly-
cerol, complete protease inhibitors) after pre-clearing using rabbit αGR antibody
(#24050–1-AP, Proteintech, 3 μg) and rabbit IgG (#2729, Cell Signaling, 3 μg) for 2
h at 4 °C and then incubated with BSA-blocked α-rabbit Dynabeads (Invitrogen)
overnight. Beads were washed 3x with wash buffer (20 mM Tris pH 8, 500 mM
KCl, 5 mM MgCl2, 0.2 mM EDTA, 20% glycerol, 1% Triton) before elution in 1 M
DTT, 6x Laemmli at 37 °C for 30 min. Western blotting was performed according
to standard protocols using mouse αGR antibody (#SC-393232, Santa Cruz,
1:1000) and mouse αE2A antibody (#SC-133075, Santa Cruz, 1:500).
Western blotting of nuclear extracts from Dex-treated wild type and E47−/−
livers was performed using rabbit αGR (#12041, Cell Signaling, 1:2000) and rabbit
αSnrp70 (ab83306, Abcam, 1:5000) antibodies.
Histology. For Oil Red O stainings on PFA-fxed liver tissue, 6μm cryosections
were incubated with Oil Red O solution (#O0625, Sigma Aldrich) in isopropyl
alcohol followed by hematoxylin (#HT110216, Sigma Aldrich). For H&E staining,
6 μm PFA-fixed liver paraffin sections were treated with hematoxylin and eosin Y
(#GHS332, Sigma Aldrich) using standard procedures. Brightfield microscopy was
performed with a Keyence BZ-9000 microscope at a magnification of ×20.
In vivo experiments. Dexamethasone (#D2915, Sigma Aldrich; to induce hyper-
glycemia) and corticosterone (#27840, Sigma Aldrich; to induce hepatic steatosis)
were dissolved in ethanol and supplied in the drinking water of mice for 3 con-
secutive weeks at a final concentration of 10ug/ml (Dex) and 100 µg/ml (Cort)18–20.
Glucose tolerance tests (GTT) were performed in mice fasted overnight. Glucose
(20% D-glucose; Sigma Aldrich) was injected i.p. at 2 g/kg and blood glucose levels
were determined using a glucometer (AccuCheck Aviva, Roche Diagnostics).
Pyruvate tolerance tests (PTT) were performed in mice fasted for 5 h. Sodium
pyruvate (#5280, Sigma Aldrich) was injected i.p. at 2 g/kg. Body composition was
measured using quantitative nuclear magnetic resonance technology (EchoMRI,
Houston, TX). For the Dex suppression test, a single dose was injected i.p. at 1 mg/
kg and mice were sacrificed 6 h later. In our hands, hyperglycemia was
reproducibly induced by our Dex protocol, while hepatosteatosis was more pro-
minent in our Cort regimen.
For fasting experiments, food was withdrawn in the late afternoon, with mice
having free access to water for the course of the experiment. Blood glucose levels
and body weight were measured at 0 h and at 24, 40 and 48 h. Mice were sacrified
after 48 h, and livers and plasma were harvested for further analysis.
Isolation of bone marrow-derived macrophages. Bone marrow derived macro-
phages were isolated and treated as described previously:9 In short, bone marrow
was harvested from murine hind legs. Erythrocytes were lysed (150 mM NH4Cl, 10
mM KHCO3, 0.2 mM EDTA). Ficoll-Paque (GE Healthcare) was used for gradient
centrifugation. Differentiation medium (DMEM, 30% L929 supernatant, 20% FBS,
1% Pen/Strep) was added on bacterial plates for 5 days. Differentiated macrophages
were counted and seeded in macrophage serum free medium (Thermo Fisher
Scientific) with 1% Pen/Strep.
Liver immunohistology. 6μm PFA-fixed liver cryosections were subjected to
antigen retrieval by boiling for 30 min in citrate-based buffer. Labeling with rabbit
αGR (#12041, Cell Signaling, 1:200) and α-rabbit Alexa 488 IgG (#A-21206, Life
technologies, 1:250) and DAPI was performed using standard protocols.
Luciferase assay screening and data analysis. GR responsive human promoter/
enhancer luciferase reporter constructs were obtained from Switchgear Genomics
(GR pathway) and transfected together with an expression vector for human GR
and a CMX-LacZ plasmid for normalization. Luciferase assays were performed in
CV-1 cells treated overnight with either vehicle, 100 nM Dexamethasone or 100
nM Cortisol as previously described9. Relative luciferase activity was compared to
vehicle and empty vector and clustered based on fold changes.
Overrepresented motifs in up- and downregulated cis-regulatory sequences
were identified using OTFBS based on TRANSFAC and aligned using T-Coffee;
motif position weight matrices were generated using Weblogo.
Mutagenesis of the two predicted E47-binding sites for ATPB2 to TTGGCC was
performed by gene synthesis (Eurofins Genomics). For Fig. 1d and e, pRL-TK
Renilla was used for normalization and luminescence was measured using the
Dual-Glo kit (Promega) according to manufacturer’s instructions.
Plasma and liver tissue analyses. Cardiac blood was collected in EDTA-coated
tubes and plasma was obtained after centrifugation. Corticosterone levels were
measured by an enzyme immunoassay kit (#K014-H1, Arbor assays) according to
the manufacturers’ instructions.
For triglyceride measurements, liver tissue was first digested in ethanol / 30%
potassium hydroxide (2:1, v/v) at 60 °C. Digested samples were mixed with 1M
MgCl2 at a ratio of 1.08:1 (volume) and incubated on ice for 10 min followed by
centrifugation. Samples were measured by colorimetric assay (#290–63701, Wako
Chemicals) following the company’s protocol.
RNA isolation, cDNA synthesis, and RT qPCR. Total RNA from tissue and cells
was isolated using the RNeasy Mini kit (Qiagen) and reverse-transcribed with the
QuantiTect Reverse Transcription Kit (Qiagen) following manufacturer’s instruc-
tions. RT-qPCR was performed using Power SYBR Green Master Mix (Life
Technologies) in a ViiA 7 Real-Time PCR System (Thermo Fischer Scientific).
Gene expression was normalized to U36b4. Primers are listed in Supplementary
Table 1b.
GR
GRE
FoxO1
Lipid & glucose
metabolism genes
E47
EBox
E47 –/–
FOX
GR
GRE
FoxO1
Lipid & glucose
metabolism genes
Med
iator
EBoxFOX
WT
Media
tor
Fig. 7 E47 modulates hepatic GR function. Graphical model summarizing our findings: In wild-type mouse livers, E47 binding at shared cis-regulatory
elements overlapping with GR and FoxO1, Mediator recruitment leads to the transcriptional activation of a subset of metabolic genes in response to GCs. In
E47 mutant mice, reduced binding of GR and FoxO1 causes a reduction of Mediator recruitment and mRNA expression of these metabolic targets, which
protects these animals from hepatic steatosis and hyperglycemia induced by GC treatment. (The liver cartoon was obtained from Servier Medical Art.)
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RNA- sequencing and data analysis. Total RNA was isolated using the RNeasy
minikit (Qiagen) (liver) or Qiazol followed by the RNeasy (muscle, fat). RNA
quality was verified using a 2100 Bioanalyzer with RNA 6000Nano Reagents
(Agilent Technologies).
Library preparation and rRNA depletion was performed using the Illumina
TruSeq stranded/unstranded mRNA Library Prep Kit v2 chemistry in an
automated system (Agilent Bravo liquid handling platform) starting with 1 μg total
RNA for each sample. Libraries were sequenced on the Illumina HiSeq2500 or
HiSeq4000. Sequencing quality was assessed with FastQC (http://www.
bioinformatics.babraham.ac.uk/ projects/fastqc/). Reads were mapped to the mouse
genome mm10 (Ensembl build 38.91) and reads per gene were counted using
STAR version 2.4.2a49. Gene count normalization and differential expression
analysis was performed using DESeq250. For gene annotation, biomaRt was used51.
Functional enrichment according to gene ontology was carried out using GOrilla52.
All scripts are deposited at github (https://github.com/FranziG/E47KO-liver).
Sequencing data, normalized count data and DESeq2 output can be accessed via
NCBI’s Gene Expression Omnibus using the accession number GSE111877.
Statistics. For differences between 2 groups, unpaired two-tailed Student’s t test
was performed. Two-way ANOVA followed by Bonferroni’s multiple comparison
test was used to compare more than 2 groups. For GTT and PTT, the area under
the curve (AUC) was calculated from the individual glucose excursion curves.
Results are given as mean ± SEM unless otherwise specified. A p value < 0.05 was
considered significant. All tests were performed using Graph Prism 6 (GraphPad
Software, San Diego, CA USA).
Data availability
All the data supporting this article are available upon reasonable request. ChIP and
RNA NGS data sets have been deposited at GEO (NCBI) [https://www.ncbi.nlm.
nih.gov/geo/]: GSE111526 (ChIP-Seq); GSE111877 (RNA-Seq). The proteomics
data have been deposited to the ProteomeXchange Consortium via PRIDE [https://
www.ebi.ac.uk/pride/archive/] with the identifier: PXD010157. Requests for
materials, reagents or correspondence should be addressed to N. H. Uhlenhaut:
henriette.uhlenhaut@helmholtz-muenchen.de.
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